Company Citi Pharma Limited

CPHL

PK0126201018

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
28.66 ^PKR	-1.55%		+0.95%	+20.72%

04-30	Citi Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
2023	Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

Citi Pharma Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. The Company's departments include API, formulation, and research and development. Its key products under the API segment include Paracetamol, Amoxicillin, Levofloxacin, Cefixime, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic acid. The Company's formulation department produces tablets, liquids, and capsules. Its research and development activities deal with various forms ranging from the development of new chemical/drug entities to the evaluation of existing products for alternative indications. Its other products include Amlodopine, Nimesulide, Mefenamic Acid, Simvastatin, Ranitiddine as Hcl, and Levofloxicen(as Hemihydrate), among others.

Number of employees: 594

PKR in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	9,780	100.0 %	12,397	100.0 %	+26.76%

PKR in Million	2022	Weight	2023	Weight	Delta
Pakistan 100.0 %	9,780	100.0 %	12,397	100.0 %	+26.76%

Managers	Title	Age	Since
Rizwan Ahmad CEO	Chief Executive Officer	-	07/10/12
Asif Iqbal DFI	Director of Finance/CFO	-	31/10/19
Zameer Ul Hassan Shah BRD	Director/Board Member	-	12/10/20
Muhammad Riaz IRO	Public Communications Contact	-	31/12/19
Muhammad Javed Rafique SAM	Sales & Marketing	-	-
Muhammad Ishaq AUD	Comptroller/Controller/Auditor	-	-
Mustafa Ghulam PRN	Corporate Officer/Principal	-	30/06/19

Members of the board	Title	Age	Since
Abdul Jaleel Shaikh BRD	Director/Board Member	-	-
Nadeem Amjad CHM	Chairman	-	07/10/12
Rizwan Ahmad CEO	Chief Executive Officer	-	07/10/12
Saira Aslam BRD	Director/Board Member	-	12/10/20
Zameer Ul Hassan Shah BRD	Director/Board Member	-	12/10/20
Muhammad Naeem BRD	Director/Board Member	-	12/10/20
Farzin Khan BRD	Director/Board Member	-	01/08/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	228,461,200	103,233,511 ( 45.19 %)	0	45.19 %

Name	Equities	%	Valuation
MCB-Arif Habib Savings & Investments Ltd. (Invt Mgmt) 2.757 %	6,298,589	2.757 %	644 598 ₨
UBL Fund Managers Ltd. 2.628 %	6,003,612	2.628 %	614 410 ₨
Atlas Asset Management Ltd. 1.616 %	3,692,523	1.616 %	377 893 ₨
NBP Fund Management Ltd. 0.5931 %	1,354,932	0.5931 %	138 664 ₨
Alfalah Asset Management Ltd. 0.0453 %	103,480	0.0453 %	10 590 ₨
JS Investments Ltd. (Investment Management) 0.0197 %	45,000	0.0197 %	4 605 ₨
ABL Asset Management Co., Ltd. 0.0120 %	27,415	0.0120 %	2 806 ₨

Citi Pharma Ltd.

588-Q Block M.A. Johar Town

54782, Lahore

http://www.citipharma.com.pk

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.66

Average target price

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
CITI PHARMA LIMITED	+20.72%	23.51M
ELI LILLY AND COMPANY	+51.82%	797B
NOVO NORDISK A/S	+39.95%	628B
MERCK & CO., INC.	+16.95%	323B
ABBVIE INC.	+9.49%	300B
ASTRAZENECA PLC	+16.70%	244B
ROCHE HOLDING AG	+0.45%	223B
NOVARTIS AG	+9.54%	214B
AMGEN INC.	+5.30%	163B
PFIZER, INC.	-6.29%	153B

Other Pharmaceuticals